Business Context and Reporting Period
Company: Acacia Research Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2002
Business Overview: Acacia operates two primary segments: the Acacia Media Technologies Group, which licenses intellectual property for telecommunications (including the "V-chip" and audio/video-on-demand), and the Acacia Life Sciences Group, primarily comprised of CombiMatrix Corporation, which develops biochip array processor systems for genomic and proteomic research.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2002 |
Six Months Ended June 30, 2002 |
Six Months Ended June 30, 2001 |
|---|---|---|---|
| Total Revenues | $438 | $687 | $12,714 |
| Operating Loss | $(13,064) | $(21,541) | $(25,738) |
| Net Loss | $(9,701) | $(16,127) | $(14,251) |
| Loss Per Share (Basic & Diluted) | $(0.49) | $(0.82) | $(0.74) |
| Cash and Cash Equivalents | $49,712 | $49,712 | $47,920 |
| Short-term Investments | $16,699 | $16,699 | $25,110 |
| Total Current Assets | $69,093 | $69,093 | $86,174 |
| Total Current Liabilities | $15,517 | $15,517 | $13,778 |
| Working Capital | $53,576 | $53,576 | $72,396 |
| Net Cash Used in Operating Activities | N/A | $(13,625) | $(7,320) |
Note: All figures in thousands except per share data. Minority interests in net loss were $4.1 million for the quarter and $6.5 million for the six months ended June 30, 2002.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues dropped significantly from $12.7 million in the six months ended June 30, 2001, to $687,000 in the same period in 2002. This is primarily due to the absence of $12.4 million in license fee income from V-chip technology settlements that occurred in 2001 but did not recur in 2002.
- Operating Expenses: Total operating expenses decreased from $38.5 million (six months 2001) to $22.2 million (six months 2002). This reduction was driven by lower marketing, general, and administrative expenses (down from $15.8M to $9.6M) and a significant decrease in non-cash stock compensation expenses (down from $15.6M to $3.6M).
- Investment Losses: The company recorded realized losses of $1.5 million and unrealized losses of $477,000 on short-term investments for the six months ended June 30, 2002. No such losses were recorded in the comparable 2001 period.
- Goodwill Accounting: Following the adoption of SFAS No. 142 on January 1, 2002, the company ceased amortizing goodwill. Consequently, amortization expense for the six months ended June 30, 2002, excluded approximately $500,000 of goodwill amortization that would have been recorded under prior standards.
Outlook, Risks, and Management Commentary
- Recapitalization Plan: Management has proposed dividing the company's common stock into two new classes: one for the CombiMatrix (Life Sciences) business and one for the Media Technologies business. This plan, along with a proposed acquisition of minority interests in CombiMatrix, is subject to stockholder approval and NASDAQ listing.
- Liquidity: As of June 30, 2002, the company held $66.4 million in cash and short-term investments. Management anticipates existing reserves will fund operations for at least the next twelve months but intends to seek additional financing for new investments.
- Key Risks:
- Patent Expiration: The V-chip patent held by Soundview Technologies expires in July 2003. The company faces uncertainty in replacing this revenue stream with new digital media technologies.
- Legal Proceedings: CombiMatrix is defending a lawsuit filed by Nanogen, Inc., alleging trade secret misappropriation and patent ownership disputes. Soundview Technologies is involved in patent infringement litigation against major television manufacturers.
- Development Stage: CombiMatrix remains in the development stage with no significant commercial product sales, relying heavily on grants and a strategic alliance with Roche Diagnostics.
- Recent Developments: In July 2002, CombiMatrix completed a milestone with Roche and a prototype for the U.S. Department of Defense. Acacia also secured a new V-chip license with Loewe Opta GmbH and a patent grant in Japan.
Investor Verification Checklist
- Verify the status and expected timeline of the proposed stock recapitalization and CombiMatrix merger.
- Monitor the outcome of the Nanogen, Inc. lawsuit against CombiMatrix regarding patent ownership and trade secrets.
- Assess the progress of new licensing agreements for digital media technologies to replace expiring V-chip revenue post-July 2003.
- Review the commercialization timeline for CombiMatrix's biochip products and the status of the strategic alliance with Roche.
- Track the company's cash burn rate relative to its $66.4 million cash position to determine the necessity of future equity or debt financing.